NeuroVive Pharmaceutical ABのボラティリティ
NeuroVive Pharmaceutical ABのボラティリティは何ですか。
NeuroVive Pharmaceutical ABのボラティリティは24.43%です。
ボラティリティの定義は何ですか。
ボラティリティまたは平均真の範囲パーセント（ATRP14）は、終値のパーセンテージとして表されるATRです。
Average true range percent (ATRP) measures volatility on a relative level. This is opposed to the ATR, which measures volatility on an absolute level. ATRP allows securities to be compared whereas ATR does not. That means lower-priced stocks won't necessarily have lower ATR values than higher-priced stocks.
The period used in the calculation is 14 days and the normalized indicator oscillates between 0 and 100 percent of recent price variation. Importantly, the indicator doesn't predict the direction of price but it describes the current volatility. The volatility is comparable across all securities and all markets.
Volatility expresses the degree of price movement. The use of ATRP as volatility compared to ATR is preferred in cases when different securities or different time periods are compared. Examples are stock screening, filtering strategies, and studying seasonality and volatility patterns over long periods of time and different markets
LSEのセクタMiscellaneousにおけるボラティリティの企業と比べるNeuroVive Pharmaceutical AB
NeuroVive Pharmaceutical ABは何をしますか。
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
NeuroVive Pharmaceutical ABと類似のボラティリティ
- Mid Wynd International Investment Trust Plcのボラティリティは24.32%です。
- Chakana Copperのボラティリティは24.32%です。
- B. Riley Incのボラティリティは24.34%です。
- Bioxyneのボラティリティは24.36%です。
- Scorpio Bulkers Incのボラティリティは24.40%です。
- Mineral & Investmentsのボラティリティは24.41%です。
- NeuroVive Pharmaceutical ABのボラティリティは24.43%です。
- Sunshine 100 China Ltdのボラティリティは24.44%です。
- Lyxor UCITS ETF PEA Dow Jones Industrial Averageのボラティリティは24.45%です。
- Polarean Imaging plcのボラティリティは24.46%です。
- First Derivatives Plcのボラティリティは24.46%です。
- Mkango Resources Ltdのボラティリティは24.48%です。
- UBS ETF - Bloomberg Barclays MSCI US Liquid Corporates Sustainable UCITS ETFのボラティリティは24.49%です。